Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/15380
Title: | CYSTIC FIBROSIS MUTATION SPECTRUM IN NORTH MACEDONIA: A STEP TOWARD PERSONALIZED THERAPY | Authors: | Terzic M Jakimovska M Fustik S Jakovska T Sukarova-Stefanovska E Plaseska-Karanfilska D |
Keywords: | cystic fibrosis (CF) CFTR mutation classes mutations |
Issue Date: | 2019 | Publisher: | Macedonian Academy of Sciences and Arts / Sciendo | Journal: | Balkan Journal of Medical Genetics | Abstract: | The most prevalent “rare” disease worldwide, cystic fibrosis (CF), is an autosomal recessive multisystem dis ease, caused by mutations in the CFTR gene. The knowledge of CFTR mutations present in certain population is important for designing a simple, fast and cost-effective genetic testing approach, also for better management of CF patients, including the administration of novel targeted therapies. Here, we present genetic results of 158 unrelated CF patients from the National CF Registry of the Republic of North Macedonia. Initially, patients were screened for the 11 most common CF mutations. Additional CF muta tions and large deletions/duplications in the CFTR gene were analyzed using commercial kits. If the genotype was undetermined, all CFTR exons were analyzed using Sanger DNA sequencing or next generation sequencing (NGS) (since 2014). The most common CF mutation, c.1521_ 1523del (legacy name F508del), was found with an over all incidence of 75.9%. Additionally, 26 other pathogenic variants and three large deletions were identified in the CFTR gene as a genetic cause of CF. Two of these, c.1070 C>T (p.Ala357Val) and c.2779_2788dup CTTGCTATGG (p.Gly930AlafsTer48), were novel. According to the distri bution and prevalence of the pathogenic variants detected in our patients, a fast and cost-effective method, based on a single base extension was designed as a first-line CF genetic test with a 90.0% detection rate within our population. Furthermore, the knowledge of CFTR mutation classes in our CF patients represents the first step toward personalized therapy for CF in our country. | URI: | http://hdl.handle.net/20.500.12188/15380 | DOI: | 10.2478/bjmg-2019-0009 |
Appears in Collections: | Faculty of Medicine: Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
BJMG,10-2019,MarijaTerzikj.pdf | 241.97 kB | Adobe PDF | View/Open |
Page view(s)
53
checked on Jul 24, 2024
Download(s)
19
checked on Jul 24, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.